Breaking News: Myriad Genetics Acquires Gateway Genomics | Learn More
For years, prostate cancer risk has been measured by PSA, Gleason score and stage, and diagnosis and treatment protocols have remained much the same. However, that traditional assessment doesn’t provide all of the information needed to appropriately stratify prostate cancer risk and determine possible treatment options.
The management of clinically localized prostate cancer presents unique challenges for you and your patients due the highly variable and often nonaggressive nature of many prostate tumors. Increased insight into the aggressiveness of an individual patient’s prostate cancer can help you make better, more informed decisions about optimal prostate cancer management.
Prolaris® is a tissue-based molecular prognostic tool that was developed to aid you in determining prostate cancer aggressiveness, in conjunction with traditional clinical parameters such as Gleason score and PSA. Prolaris measures the expression level of genes involved with tumor proliferation to predict disease outcome, and it has been validated to predict prostate cancer-specific disease progression in several published clinical trials.1-6
By combining traditional risk factors with a molecular assessment of the aggressiveness of an individual patient’s prostate cancer, you have the information you need to make the most informed treatment decisions. Prolaris can assist you in identifying low or intermediate-risk patients who may be candidates for active surveillance, as well as patients who might be at potentially higher risk and would benefit from closer monitoring or more aggressive therapy. With the aid of molecular prognostic testing such as Prolaris, you can help reduce patient uncertainty and feel more confident about providing personalized patient care.
Prolaris testing is easy and appropriate for patients diagnosed with localized prostate cancer.